There is no fixed duration. The old recommendation of "lowest dose, shortest time" has been revised. Current practice supports continuing HRT as long as the benefits outweigh the risks for the individual patient, with periodic reassessment. Some women use HRT for 5 years, others for 20 or more.
The “5 years maximum” guideline that many doctors still cite originated from early WHI interpretations and was never an evidence-based hard limit. Subsequent research has shown that the risk-benefit profile depends on the individual, not a timer.
Factors that influence duration include the severity of ongoing symptoms, bone density, cardiovascular risk profile, breast cancer risk, type of HRT used (estrogen-only vs. combined), and quality of life on versus off treatment.
Estrogen-only HRT (for women without a uterus) carries a lower long-term risk profile than combined estrogen-progesterone therapy. The breast cancer risk associated with combined HRT is small and comparable to risks from obesity, alcohol use, and sedentary lifestyle — context that is often left out of the conversation.
Some women attempt to stop HRT and find that symptoms return. This is not a failure — it is information. If quality of life is significantly better on HRT and monitoring shows acceptable risk markers, continuing is a valid medical decision.
At Viking, your provider discusses duration as part of your ongoing protocol reviews, adjusting dose and delivery method as your needs change over time.